prazepam ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
diazepam derivatives 2240 2955-38-6

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • prazepam
  • sedapran
  • trepidan
  • verstran
  • prazene
A benzodiazepine that is used in the treatment of ANXIETY DISORDERS.
  • Molecular weight: 324.81
  • Formula: C19H17ClN2O
  • CLOGP: 3.93
  • LIPINSKI: 0
  • HAC: 3
  • HDO: 0
  • TPSA: 32.67
  • ALOGS: -4.91
  • ROTB: 3

  • Status: OFM

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
30 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.00 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 0 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 3.08 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD

Approvals:

DateAgencyCompanyOrphan
None FDA PARKE DAVIS

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Poisoning deliberate 365.57 38.28 89 3421 7823 50593791
Coma 261.65 38.28 110 3400 56769 50544845
Somnolence 177.11 38.28 118 3392 154867 50446747
Altered state of consciousness 116.10 38.28 47 3463 21863 50579751
Suicide attempt 104.63 38.28 57 3453 51675 50549939
Drug dependence 103.35 38.28 42 3468 19717 50581897
Drug abuse 99.52 38.28 58 3452 59788 50541826
Mydriasis 97.16 38.28 34 3476 10593 50591021
Intentional overdose 94.58 38.28 57 3453 62447 50539167
Toxicity to various agents 81.16 38.28 86 3424 212413 50389201
Hepatocellular injury 64.93 38.28 33 3477 25914 50575700
Miosis 64.69 38.28 22 3488 6288 50595326
Electrocardiogram QT prolonged 62.55 38.28 41 3469 51845 50549769
Hypotonia 59.23 38.28 22 3488 8112 50593502
Prescription form tampering 56.69 38.28 12 3498 556 50601058
Hypotension 48.62 38.28 70 3440 235399 50366215
Respiratory acidosis 46.45 38.28 17 3493 6011 50595603
Confusional state 43.92 38.28 59 3451 185869 50415745
Vasoplegia syndrome 43.64 38.28 11 3499 1103 50600511
Sopor 43.17 38.28 23 3487 19856 50581758
Overdose 42.67 38.28 43 3467 99684 50501930
Hyperlactacidaemia 39.36 38.28 12 3498 2421 50599193
Prothrombin time shortened 39.24 38.28 11 3499 1656 50599958

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Coma 222.10 41.04 83 1575 39367 29533502
Miosis 105.28 41.04 32 1626 7977 29564892
Somnolence 80.04 41.04 55 1603 93900 29478969
Drug abuse 78.20 41.04 51 1607 79832 29493037
Poisoning deliberate 71.45 41.04 22 1636 5709 29567160
Housebound 69.98 41.04 12 1646 220 29572649
Bladder dilatation 49.29 41.04 12 1646 1296 29571573
Pneumonia aspiration 44.73 41.04 27 1631 36710 29536159

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Coma 449.25 30.84 191 5006 87424 64406111
Poisoning deliberate 400.38 30.84 110 5087 13348 64480187
Somnolence 248.54 30.84 171 5026 203474 64290061
Miosis 155.22 30.84 53 5144 13213 64480322
Suicide attempt 134.63 30.84 79 5118 70928 64422607
Altered state of consciousness 131.08 30.84 63 5134 37839 64455696
Mydriasis 118.27 30.84 45 5152 15267 64478268
Intentional overdose 115.07 30.84 78 5119 89866 64403669
Drug abuse 113.22 30.84 90 5107 132284 64361251
Hepatocellular injury 79.57 30.84 48 5149 45187 64448348
Toxicity to various agents 79.32 30.84 120 5077 363393 64130142
Bladder dilatation 73.25 30.84 19 5178 1835 64491700
Respiratory acidosis 69.07 30.84 27 5170 9828 64483707
Drug dependence 65.51 30.84 38 5159 33274 64460261
Housebound 57.28 30.84 12 5185 453 64493082
Hypotension 56.61 30.84 106 5091 380868 64112667
Electrocardiogram QT prolonged 53.26 30.84 47 5150 79401 64414134
Hypotonia 49.18 30.84 22 5175 11190 64482345
Overdose 43.96 30.84 59 5138 159507 64334028
Wrong patient received product 43.85 30.84 15 5182 3747 64489788
Confusional state 42.94 30.84 76 5121 261068 64232467
Tachycardia 40.73 30.84 55 5142 149524 64344011
Hyperkalaemia 40.18 30.84 45 5152 101084 64392451
Vasoplegia syndrome 40.09 30.84 13 5184 2754 64490781
Fall 39.86 30.84 97 5100 416729 64076806
Disturbance in attention 39.51 30.84 30 5167 41044 64452491
Antipsychotic drug level increased 39.35 30.84 15 5182 5100 64488435
Pneumonia aspiration 35.64 30.84 33 5164 59238 64434297
Chronic actinic dermatitis 33.89 30.84 5 5192 21 64493514
Sopor 33.80 30.84 24 5173 29637 64463898
Retroplacental haematoma 32.60 30.84 6 5191 114 64493421
Prothrombin time shortened 31.81 30.84 11 5186 2838 64490697
Prothrombin time ratio decreased 30.91 30.84 8 5189 765 64492770

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC N05BA11 NERVOUS SYSTEM
PSYCHOLEPTICS
ANXIOLYTICS
Benzodiazepine derivatives
MeSH PA D014151 Anti-Anxiety Agents
MeSH PA D002491 Central Nervous System Agents
MeSH PA D002492 Central Nervous System Depressants
MeSH PA D018682 GABA Agents
MeSH PA D018757 GABA Modulators
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D011619 Psychotropic Drugs
MeSH PA D014149 Tranquilizing Agents

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Anxiety indication 48694002
Insomnia indication 193462001
Suicidal thoughts contraindication 6471006
Disorder of lung contraindication 19829001 DOID:850
Borderline personality disorder contraindication 20010003 DOID:10930
Alcohol intoxication contraindication 25702006
Shock contraindication 27942005
Depressive disorder contraindication 35489007
Substance abuse contraindication 66214007
Psychotic disorder contraindication 69322001
Sleep apnea contraindication 73430006 DOID:0050847
Decreased respiratory function contraindication 80954004
Kidney disease contraindication 90708001 DOID:557
Hypoalbuminemia contraindication 119247004
Disease of liver contraindication 235856003 DOID:409
Sleep automatism contraindication 247962006
Pregnancy, function contraindication 289908002
Coma contraindication 371632003
Porphyria contraindication 418470004
Behavioral Disorders contraindication




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 2.89 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
GABA-A receptor alpha-1/beta-2/gamma-2 Ion channel POSITIVE ALLOSTERIC MODULATOR WOMBAT-PK CHEMBL

External reference:

IDSource
4018633 VUID
N0000146946 NUI
D00470 KEGG_DRUG
4018633 VANDF
C0032910 UMLSCUI
CHEBI:8362 CHEBI
CHEMBL969 ChEMBL_ID
DB01588 DRUGBANK_ID
D011222 MESH_DESCRIPTOR_UI
4890 PUBCHEM_CID
7275 IUPHAR_LIGAND_ID
1727 INN_ID
Q30VCC064M UNII
8627 RXNORM
001459 NDDF
387417001 SNOMEDCT_US
74065006 SNOMEDCT_US

Pharmaceutical products:

None